Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the exact moment Amphastar Pharmaceuticals discloses an FDA manufacturing observation or a change in its insulin API strategy can feel like hunting for a needle in a 300-page haystack. Because every cGMP deviation, pipeline update, and recall risk must be reported, AMPH’s SEC documents are dense with technical language that even seasoned analysts find daunting.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries that translate each filing into plain English. Want the highlights of an Amphastar Pharmaceuticals annual report 10-K simplified? Our platform extracts segment revenues, R&D spend, and key FDA milestones in seconds. Need the latest Amphastar Pharmaceuticals quarterly earnings report 10-Q filing? It arrives with instant ratios and trend graphs. Form 8-K material events—such as trial results or supply-chain contracts—are pushed to you with Amphastar Pharmaceuticals 8-K material events explained so you never miss a market-moving update.
For governance insights, track Amphastar Pharmaceuticals insider trading Form 4 transactions the moment executives file; our alerts surface patterns in Amphastar Pharmaceuticals executive stock transactions Form 4. Dig into the proxy for Amphastar Pharmaceuticals proxy statement executive compensation or explore Amphastar Pharmaceuticals earnings report filing analysis to compare margin shifts. Whether you’re understanding Amphastar Pharmaceuticals SEC documents with AI for compliance checks or evaluating competitive position, Stock Titan’s coverage of every 10-K, 10-Q, 8-K, S-1, and real-time Amphastar Pharmaceuticals Form 4 insider transactions gives you the clarity and speed required to make informed decisions.
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.
On 06/30/2025, Quest Resource Holding Corp. (QRHC) director Sarah Tomolonius reported the acquisition of 1,732 deferred stock units (DSUs) at an indicated price of $2.02 per unit, under the company’s 2024 Incentive Compensation Plan. These DSUs will convert into common shares when the director separates from the company.
After the transaction, Tomolonius beneficially owns 28,196 DSUs—18,027 granted in 2012 and 10,169 granted in 2024—plus 13,926 common shares held outright. Her total economic exposure therefore rises to approximately 42,122 shares. Ownership remains direct and no derivative securities were involved.
The purchase modestly increases insider alignment but is not material relative to QRHC’s overall share count or trading volume. No indication of a Rule 10b5-1 trading plan was disclosed, and no additional executive or strategic information accompanied the filing.
FAQ
What is the current stock price of Amphastar Pharma (AMPH)?
What is the market cap of Amphastar Pharma (AMPH)?
What is Amphastar Pharmaceuticals' core business?
What types of products does Amphastar produce?
How do Amphastar's manufacturing facilities support its operations?
What role does research and development play at Amphastar?
How does Amphastar distribute its products?
What distinguishes Amphastar in the competitive pharmaceutical landscape?
Can you explain the significance of cGMP compliance for Amphastar?
How does Amphastar manage regulatory challenges?
